This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/bindingdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n31http://linked.opendata.cz/resource/AHFS/
n17http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/mesh/concept/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/drugbank/
n29http://www.rxlist.com/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/national-drug-code-directory/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/chemspider/
n6http://linked.opendata.cz/resource/drugbank/patent/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n4http://linked.opendata.cz/ontology/drugbank/
n32http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00398/identifier/pdb/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00398
rdf:type
n4:Drug
n4:description
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
n4:dosage
n10:271B436A-363D-11E5-9242-09173F13E4C5 n10:271B4369-363D-11E5-9242-09173F13E4C5
n4:generalReferences
# FDA label
n4:group
investigational approved
n4:halfLife
25-48 hours
n4:indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
n4:manufacturer
n17:271B4367-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00398 n30:DB00398
dcterms:title
Sorafenib
adms:identifier
n8:D08524 n9:Sorafenib n18:216239 n19:46505329 n20:BAX n21:PA7000 n22:16673 n23:DB00398 n24:50419-488-58 n25:50924 n27:187440
n4:mechanismOfAction
Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited.
n4:packager
n17:271B4366-363D-11E5-9242-09173F13E4C5
n4:patent
n6:2315715 n6:7235576 n6:2359510
n4:routeOfElimination
Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of the dose excreted in urine as glucuronidated metabolites.
n4:synonym
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea Sorafenibum 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
n4:toxicity
The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.
n13:hasAHFSCode
n31:92-00-00
n4:proteinBinding
99.5% bound to plasma proteins.
n4:salt
n4:synthesisReference
Ales Gavenda, Alexandr Jegorov, Pierluigi Rossetto, Peter Lindsay MacDonald, Augusto Canavesi, "POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF." U.S. Patent US20090192200, issued July 30, 2009.
n15:hasConcept
n16:M0446095
foaf:page
n29:nexavar-drug.htm n32:sorafenib.html
n4:IUPAC-Name
n5:271B436F-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B4375-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B4374-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B4371-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B4372-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B4373-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B4385-363D-11E5-9242-09173F13E4C5 n5:271B436D-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B4386-363D-11E5-9242-09173F13E4C5 n5:271B436B-363D-11E5-9242-09173F13E4C5 n5:271B436E-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B436C-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:L01XE05
n4:H-Bond-Acceptor-Count
n5:271B437B-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B437C-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B4376-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B4377-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B4379-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B4378-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B437A-363D-11E5-9242-09173F13E4C5
n4:absorption
The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma levels in 3 hours following oral administration. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
284461-73-0
n4:category
n4:containedIn
n26:271B4368-363D-11E5-9242-09173F13E4C5
n4:Bioavailability
n5:271B4381-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B4383-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B4384-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B4380-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B437F-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B4382-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B4370-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B437D-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B437E-363D-11E5-9242-09173F13E4C5